Cardiac Science Announces First Quarter Results.

IRVINE, Calif.--(BW HealthWire)--May 18, 1998--Cardiac Science Inc. (OTC/BB:DFIB), the developer of the recent FDA-cleared fully automatic hospital bedside defibrillator-monitor, reported revenues of $446,712 and a net loss of $711,506, or 14 cents a share, for the three months and year to date ended March 31, 1998 compared with no revenues and a net loss of $168,475, or 5 cents a share for the three months and year to date ended March 31, 1997.

"Revenue in the quarter is attributed to strong international demand for our subsidiary's Holter ECG products. We are pleased this business continues its pattern of growth, while we devote substantial financial and human resources to completing the commercial model of the Powerheart(R) automatic defibrillator-monitor," said Raymond W. Cohen, president and chief executive officer.

The Powerheart(R) Automatic External Cardioverter Defibrillator, a non-invasive bedside defibrillator used to continuously monitor hospitalized cardiac patients for life-threatening heart rhythms, delivers defibrillation shocks within seconds and without human intervention should a patient suffer cardiac arrest.

Cardiac Science is committed to developing propriety devices that increase the survival rates of cardiac arrest victims. The Powerheart AECD(R), in controlled multicenter clinical studies, demonstrated a sensitivity of 100 percent (correctly identifying shockable episodes), a specificity of 99.4 percent (not allowing a non-shockable rhythm to be shocked), first shock efficacy of 96.2 percent with energy levels as low as 50 joules and an average response time of 21 seconds, indicating that it is an accurate and reliable tool in helping to save people from in-hospital cardiac arrest.

Cardiac Science, through its subsidiary Diagnostic Monitoring, manufactures Ambulatory Holter ECG recorders and PC-based Holter systems and distributes these products in the United States and in over 40 countries. For more information, visit the company's Web sites at www.cardiacscience.com and www.diagnosticmonitoring.com. -0-

                         Cardiac Science Inc.
             Consolidated Condensed Summary of Operations

                                           3 Months Ended March 31
                                       ------------------------------
                                            1998            1997
                                       --------------  --------------
Total Revenues                         $     446,712   $         ---
Net Loss                               $    (711,506)  $    (168,475)
Basic and diluted loss per share       $       (0.14)  $       (0.05)
Number of shares used in the
 computation of loss per share             4,984,560       3,424,561

This news release contains forward-looking statements, including but not limited to those regarding Cardiac Science's ability to improve patient-care, increase survival rates for in-hospital cardiac arrest victims, and reduce patient care costs. Actual results could vary materially from the description contained herein due to many factors, including hospital operations, market and clinical users' acceptance of new and existing products, impact of competitive products and pricing, changing market conditions, and risks detailed in the company's Form 10-KSB for the year ending Dec. 31, 1997 and other documents filed with the Securities and Exchange Commission. The company does not undertake any obligation to update the information contained herein, which speaks only as of this date. -0-

The Powerheart(R) and AECD(R) are registered trademarks of Cardiac Science Inc.

CONTACT: Cardiac Science Inc., Irvine

Brett L. Scott, 949/587-0357